Business Context and Reporting Period
This Form 8-K filing by Progyny, Inc. (PGNY) reports a significant executive leadership change. The report date is December 12, 2025, with the event effective as of December 31, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of President: Michael Sturmer, President of Progyny, Inc., will cease employment effective December 31, 2025.
- Succession Plan: The Company is not naming a successor to the role of President, citing enhanced executive leadership depth added over the past two years (including a Chief Commercial Officer, Chief Technology Officer, Chief Operating Officer, and Chief Product Officer).
- Consulting Arrangement: Mr. Sturmer will transition to a non-employee consultant role through December 31, 2026, to ensure continuity of strategic initiatives.
Compensation and Contingencies
- Severance: Mr. Sturmer is entitled to severance payments and benefits per his employment agreement dated December 17, 2021.
- Consulting Fee: An annual advisory fee of $250,000 is established under the new Consulting Agreement.
- Option Extension: If Mr. Sturmer provides services through June 30, 2026, his outstanding and vested options will remain exercisable beyond their existing expiration date for a proportional period.
Investor Verification Checklist
- Review the full text of the Consulting Agreement when filed as an exhibit to the 2025 Form 10-K.
- Verify the specific terms of the December 17, 2021 employment agreement to understand the exact severance package details.
- Monitor future filings for the appointment of interim leadership or further restructuring of the executive team.